NT
NTRA.US Natera Inc
- Market cap
- USD 46.3B
- P/E
- -
- P/B
- 24.75x
- ROE
- -15.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NTRA.US undervalued?
Graham numberThe Graham number of Natera Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Natera Inc fundamental analysis
No fundamental analysis for Natera Inc yet.
Natera Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. T…
Full company profileNatera Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Natera Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 217M | 211M | 258M | 302M | 391M | 625M | 820M | 1.08B | 1.70B | 2.31B | 2.99B |
| Gross Profit | 81.5M | 71.3M | 91.6M | 127M | 187M | 307M | 364M | 493M | 1.02B | 1.50B | 1.93B |
| Operating Income | -96.5M | -134M | -115M | -116M | -216M | -468M | -541M | -446M | -222M | -310M | -317M |
| EBITDA | -93.4M | -126M | -107M | -104M | -206M | -452M | -521M | -398M | -148M | -221M | -196M |
| Net Income | -95.8M | -136M | -128M | -125M | -230M | -472M | -548M | -435M | -190M | -208M | -283M |
| EPS | -1.86 | -2.54 | -2.22 | -1.79 | -2.84 | -5.21 | -5.57 | -3.78 | -1.53 | -1.52 | -1.96 |
| Balance Sheet | |||||||||||
| Total Assets | 211M | 215M | 268M | 583M | 932M | 1.24B | 1.39B | 1.44B | 1.66B | 2.40B | 2.75B |
| Total Liabilities | 104M | 189M | 236M | 304M | 446M | 583M | 689M | 676M | 465M | 686M | 879M |
| Shareholders' Equity | 106M | 25.4M | 32.2M | 279M | 486M | 653M | 706M | 765M | 1.20B | 1.71B | 1.87B |
| Cash & Short-term Investments | 146M | 119M | 154M | 441M | 737M | 914M | 898M | 879M | 968M | 1.08B | 1.10B |
| Total Debt | 49.6M | 123M | 124M | 156M | 281M | 397M | 446M | 442M | 187M | 214M | 239M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -74.1M | -97.8M | -70.6M | -63.4M | -183M | -335M | -432M | -247M | 136M | 215M | 185M |
| Capital Expenditure | 23.1M | 9.87M | 3.88M | 4.97M | 19.6M | 41.0M | 47.7M | 39.2M | 66.4M | 106M | 166M |
| Free Cash Flow | -97.2M | -108M | -74.5M | -68.4M | -202M | -376M | -479M | -286M | 69.2M | 109M | 19.5M |
| Ratios | |||||||||||
| ROE | -89.9% | -536.3% | -398.5% | -44.8% | -47.2% | -72.2% | -77.6% | -56.8% | -15.9% | -12.2% | -15.1% |
| ROA | -45.5% | -63.5% | -47.8% | -21.4% | -24.6% | -38.1% | -39.3% | -30.2% | -11.5% | -8.7% | -10.3% |
| Net Profit Margin | -44.1% | -64.6% | -49.7% | -41.3% | -58.8% | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% | -9.4% |
| Debt to Equity | 0.47x | 4.85x | 3.84x | 0.56x | 0.58x | 0.61x | 0.63x | 0.58x | 0.16x | 0.13x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Natera Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 30.0M | 0.30 | - |
| 2021 | - | - | - |
| 2020 | USD 7.11M | 0.09 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Natera Inc
- Insiders 2.96%
- Institutions 97.04%
- Public & others 0.00%
- Shares outstanding 145M
- Free float 141M
Top funds holding NTRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| JPMorgan Large Cap Growth I | 6.02M | 4.15% | -0.91% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.35M | 3.00% | +0.59% | Sep 2026 |
| Vanguard Small Cap Index | 3.08M | 2.13% | -1.55% | Sep 2026 |
| Fidelity Contrafund | 2.72M | 1.88% | +34.31% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.72M | 1.18% | -4.53% | Sep 2026 |
| American Funds Growth Fd of Amer A | 1.52M | 1.05% | +53.31% | Sep 2026 |
| Franklin DynaTech Fund A | 1.50M | 1.03% | 0.00% | Sep 2026 |
| MFS Mid Cap Growth A | 1.35M | 0.93% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.05M | 0.72% | -0.32% | Oct 2026 |
| T. Rowe Price Mid-Cap Growth | 859K | 0.59% | +3.88% | Sep 2026 |
| iShares Russell Mid-Cap Growth ETF | 769K | 0.53% | -0.07% | Oct 2026 |
| JPMorgan Mid Cap Growth I | 695K | 0.48% | -16.76% | Sep 2026 |
| Fidelity Extended Market Index | 660K | 0.46% | -5.43% | Sep 2026 |
| JPMorgan Growth Advantage A | 619K | 0.43% | -2.20% | Sep 2026 |
| Vanguard US Growth Investor | 593K | 0.41% | -23.49% | Sep 2026 |
| T. Rowe Price Lrg Cp Gr I | 582K | 0.40% | -22.10% | Sep 2026 |
| Fidelity Select Health Care | 580K | 0.40% | +49.43% | Aug 2026 |
| iShares Russell Mid-Cap ETF | 580K | 0.40% | -0.06% | Oct 2026 |
| Fidelity Contrafund K6 | 580K | 0.40% | +34.27% | Sep 2026 |
| T. Rowe Price New Horizons | 550K | 0.38% | -22.99% | Sep 2026 |
Top institutions holding NTRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| JPMorgan Chase & Co | 12.9M | 8.87% | -3.89% | Jun 2026 |
| BlackRock Inc | 10.9M | 7.53% | +2.22% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 9.02M | 6.22% | -25.96% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.23M | 4.30% | +3.66% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.78M | 3.99% | +2.44% | Jun 2026 |
| FMR Inc | 5.45M | 3.76% | +113.42% | Jun 2026 |
| Wellington Management Company LLP | 4.04M | 2.79% | -15.26% | Jun 2026 |
| State Street Corp | 3.66M | 2.52% | +6.97% | Jun 2026 |
| Duquesne Family Office LLC | 3.19M | 2.20% | +4.01% | Jun 2026 |
| Geode Capital Management, LLC | 2.75M | 1.90% | -0.93% | Jun 2026 |
| Franklin Templeton Inc | 2.73M | 1.88% | +9.68% | Jun 2026 |
| Castle Hook Partners LP | 2.60M | 1.79% | +2.63% | Jun 2026 |
| Coatue Management LLC | 2.51M | 1.73% | -1.45% | Jun 2026 |
| AQR Capital Management LLC | 2.34M | 1.62% | +3.10% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 2.22M | 1.53% | -30.84% | Jun 2026 |
| Massachusetts Financial Services Company | 1.97M | 1.36% | -3.37% | Jun 2026 |
| NORGES BANK | 1.83M | 1.26% | +12.46% | Jun 2026 |
| Fred Alger Management, LLC | 1.78M | 1.23% | +1.23% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.72M | 1.19% | +124.20% | Jun 2026 |
| Sofinnova Ventures | 1.55M | 1.07% | 0.00% | Jun 2026 |
Natera Inc company profile
- Company name
- Natera Inc
- Ticker
- NTRA.US
- Exchange
- USA Stocks
- Listed since
- Jul 2, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,135
- Fiscal year end
- December
- Address
- 13011 McCallen Pass, Austin, TX, United States, 78753
- Phone
- 650 980 9190
- Website
- natera.com
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Natera Inc management
10- Dr. Matthew Rabinowitz Ph.D.Co-Founder & Executive Chairman · born 1973
- Mr. Steven Leonard ChapmanCEO & Director · born 1979
- Mr. John FeskoPresident & Chief Business Officer · born 1979
- Mr. Michael B. Brophy M.B.A.Chief Financial Officer · born 1980
- Mr. Solomon Moshkevich M.B.A.President of Clinical Diagnostics · born 1982
- Mr. Jonathan Sheena M.Eng.Co-Founder & Director · born 1973
- Ms. Olesya A. Anisimova CPAChief Accounting Officer
- Mr. Rishi KackerChief Technology Officer
- Mr. Eric A. Evans Ph.D.Chief Scientific Officer
- Mr. Daniel Rabinowitz L.L.M.Secretary & Chief Legal Officer · born 1969